Skip to main content
main-content

Hepatology

Hepatology

03-12-2018 | Oncology | News | Article

Positive FDA decisions for lorlatinib, talazoparib, pembrolizumab

Read more about these approvals here

15-11-2018 | Oncology | Main feed | News

Postoperative HCC recurrence surveillance should target the liver

Clinicians monitoring patients for late recurrence after curative surgery for hepatocellular carcinoma should focus on the liver, say Chinese researchers who found few patients develop only extrahepatic disease in the first instance.

22-08-2018 | Oncology | News | Article

FDA announces approvals for metastatic SCLC, unresectable HCC

Click through to see which drugs are now available for these patient populations

14-08-2018 | Oncology | News | Article

Preoperative antivirals lower recurrence risk in HBV-related liver cancer

Patients who receive antiviral therapy for more than 90 days prior to hepatectomy for hepatitis B virus-related hepatocellular carcinoma have a reduced risk for microvascular invasion and early tumor recurrence, Chinese research shows.

03-08-2018 | HBV | News | Article

HCC risk score developed for patients with chronic hepatitis B virus

Researchers have developed and validated a score for predicting the risk for hepatocellular carcinoma in Asian patients with chronic hepatitis B virus infection who are taking oral antiviral therapy.

03-08-2018 | HBV | News | Article

HCC risk remains even after achieving positive HBV outcomes

Two meta-analyses published in the Journal of Viral Hepatitis confirm that patients with hepatitis B virus infection remain at risk for hepatocellular carcinoma even after achieving positive virologic outcomes, and identify factors associated with the risk.

03-08-2018 | HBV | News | Article

Global HBV prevalence estimated at 3.9%

More than 290 million people, or 3.9% of the global population, are infected with hepatitis B virus, and while efforts to combat infection are improving, greater access to diagnosis and treatment is needed to meet global targets, report The Polaris Observatory Collaborators.

05-07-2018 | Oncology | News | Article

Advanced HCC survival boost with cabozantinib

Patients with previously treated advanced hepatocellular carcinoma may derive a survival advantage from treatment with the multikinase inhibitor cabozantinib, CELESTIAL trial results indicate.

03-05-2018 | HBV | News | Article

Updated AASLD guidance released on HBV prevention, diagnosis, and treatment

The American Association for the Study of Liver Diseases has issued a guidance statement for chronic hepatitis B virus, covering topics ranging from screening and prevention through to the clinical management of patients.

03-05-2018 | HBV | News | Article

End of treatment HBsAg levels may predict HBV relapse

Hepatitis B surface antigen levels at the end of treatment or prophylaxis with nucleos(t)ide analog inhibitors could be a useful indicator of hepatitis B virus relapse, suggest two Taiwanese studies.

03-05-2018 | HBV | News | Article

‘Excellent’ survival with long-term TDF, entecavir treatment of chronic HBV

Caucasian patients with chronic hepatitis B virus infection who receive long-term therapy with tenofovir disoproxil fumarate or entecavir have “excellent” survival, which is comparable to that of the general population, say researchers.

01-02-2018 | HBV | News | Article

Diabetes linked to elevated HCC risk after HBsAg seroclearance

Diabetes remains an independent risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection even after hepatitis B surface antigen seroclearance, findings indicate.

22-12-2017 | HBV | News | Article

FIB-4 index identifies chronic HBV patients with lowest HCC risk

The noninvasive fibrosis-4 index can further refine the existing favorable clinical profile for hepatocellular carcinoma risk in noncirrhotic patients with chronic hepatitis B virus infection and help identify those with the lowest risk, say researchers.

22-12-2017 | HBV | News | Article

Serum HBV RNA may represent noninvasive marker for HBV progression

Serum hepatitis B virus RNA levels correlate with viral transcriptional activity and histologic changes in the livers of patients with chronic HBV who are receiving nucleos(t)ide analog therapy, Chinese researchers report.

15-12-2017 | HBV | News | Article

Durability of HBsAg clearance induced by NA therapy demonstrated

Clearance of hepatitis B surface antigen with nucleos(t)ide analogs is as durable as spontaneous clearance in patients with chronic hepatitis B virus infection, researchers report.

15-12-2017 | HBV | News | Article

HBV remains major contributor to primary liver cancer globally

Hepatitis B virus infection is the leading cause of incident primary liver cancer and associated mortality worldwide, according to research published in JAMA Oncology.

11-12-2017 | HBV | News | Article

Partial TDF responders achieve virologic response with treatment continuation

Most patients with chronic hepatitis B virus infection initially classed as partial responders to treatment with tenofovir disoproxil fumarate achieve a virologic response without additional treatment adjustment, research suggests.

11-12-2017 | HBV | News | Article

HCC, mortality risk remains for untreated immune tolerant-phase HBV patients

Being in the immune tolerant phase of chronic hepatitis B virus (HBV) infection is no assurance against the risk for developing hepatocellular carcinoma (HCC), requiring liver transplantation, or dying, say South Korean investigators.

29-09-2017 | HBV | News | Article

Novel indices to diagnose fibrosis in chronic HBV patients developed

Two research groups have developed noninvasive indices to detect significant fibrosis in treatment-naïve patients with chronic hepatitis B virus infection, one using serum levels of Golgi protein 73 and liver stiffness, and the other based on the ratio of gamma-glutamyl transpeptidase to albumin.

27-07-2017 | HBV | News | Article

Temporal liver cancer trends in HBV-endemic population mapped

A South Korean population-based study shows an increase in liver cancer burden over a 14-year period, while another analysis in the same population shows an improvement in the survival of patients with hepatocellular cancer in the past decade.

Image Credits